From a study on the lack of racial diversity in clinical research to appeals for improved clinical trial reporting, this week’s Research Ethics Roundup looks at new policy concerns for the research community.
1. Why Social Media Needs to Have a Code of Ethics for Clinical Research: In this opinion piece for CIO Magazine, Eric Swirsky argues that the clinical research community needs to develop detailed research guidelines for research done with social media data. He points out that social media users may not fully [...] Read more
This week’s Research Ethics Roundup looks at several controversial issues emerging in the medical research field including whether clinical trials should be conducted on the use of psychiatric medications in infants.
From Eli Lilly abandoning evacetrapib in the final stages of trials to the surprising placebo effect, this week’s Research Ethics Roundup shines the spotlight on clinical trials that could shape the future of research.
Gene Editing Record Smashed in Pigs: A team from Harvard Medical School, led by geneticist George Church, has used CRISPR technology to modify more than 20 genes in pig embryo and deactivate more than 60 viruses that could cause disease in human [...] Read more
On July 10, 2015, the US House of Representatives passed H.R. 6, the 21st Century Cures Act, with a vote of 344-77. The passage of the bill, which many have hailed as a noteworthy example of bipartisan collaboration, is the result of more than a year of congressional hearings, roundtable discussions, whitepapers, and political debate. First introduced in April 2014 by Fred Upton (R-MI), chairman of the US House of Representatives’ Energy and Commerce Committee, and Representative Diana DeGette (D-CO), the 21st Century Cures initiative seeks to "accelerate the pace of cures in America."
The legislative phase of the 21st [...] Read more
In this week's Research Ethics Roundup, we explore some of the ethical and practical questions posed by new innovations in the research enterprise, as well as some age old concerns, such as the recruitment of subjects for clinical trials. Read on:
FDA, Sponsors Look to Expand Patient Input to Clinical Trials: The involvement of patient groups in the design of clinical trials is becoming increasingly common. In this article for Applied Clinical Trials, Jill Wechsler reports on this shift, as well as the Food and Drug Administration's efforts to foster patient-focused drug development.